Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06751238 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06751238 · ClinicalTrials.gov record · last posted 2026-08-21

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Name: Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). — clinical trial record (NCT06751238)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorNovartis Pharmaceuticals

Started2025-09-24

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA

Protocol amendment history 3 changes detected by DataLookout

2026-08-22

Trial sites expanded: 8 → 11 locations

2026-08-22

Primary completion moved earlier: 2032-11-30 → 2029-10-31

2026-08-22

Completion moved earlier: 2032-12-01 → 2031-03-11

Trial Details

NCT Number	NCT06751238
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Juvenile Psoriatic Arthritis
Enrollment	20 participants
Start Date	2025-09-24
Primary Completion	2029-10-31 (estimated)
Study Completion	2031-03-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-21